New Kisqali Combination Joins Verzenios In England’s Cancer Drugs Fund

 
• By Neena Brizmohun

Two of the three companies vying for an additional share of England’s CDK4/6 inhibitor market have now secured reimbursement for the use of their products in combination with fulvestrant for advanced breast cancer.

Funding
Novartis has secured reimbursement for Kisqali in England • Source: Shutterstock

More from Market Access

More from Pink Sheet